The therapeutic goalposts for type 2 diabetes have shifted decisively. What began as glucose management has evolved into a multi-organ protection strategy — and a comprehensive review in Endocrine Reviews now maps exactly how three drug classes should be staged across the full spectrum of cardiovascular-kidney-metabolic (CKM) disease, offering clinicians and patients a clearer framework for sequential, evidence-based intervention.
The review synthesizes evidence from landmark cardiovascular outcomes trials to construct a staged treatment architecture across the CKM continuum. At early stages (obesity and prediabetes without established organ damage), weight-centric incretin therapy — GLP-1 receptor agonists or newer dual agonists targeting both GIP and GLP-1 receptors — is prioritized. As kidney involvement emerges with albuminuria or heart failure risk, SGLT2 inhibitors move to the front line, with GLP-1 receptor agonists added when cardiovascular burden or obesity predominates. In advanced CKM disease, the analysis recommends layered combination therapy: SGLT2 inhibitor plus GLP-1 receptor agonist or dual incretin, with the addition of finerenone — a non-steroidal mineralocorticoid receptor antagonist — for persistent albuminuria. Across all stages, the benefits highlighted extend far beyond glycemic lowering, encompassing reductions in major adverse cardiovascular events and attenuation of chronic kidney disease progression.
This framework matters because it synthesizes a fragmented but rapidly expanding evidence base into a clinically actionable sequence. SGLT2 inhibitors have demonstrated kidney and heart failure benefits in multiple large randomized trials, including CREDENCE, DAPA-CKD, and EMPEROR-Reduced. GLP-1 receptor agonists have shown cardiovascular mortality reductions in LEADER and SUSTAIN-6, while tirzepatide's dual incretin profile adds substantial weight reduction. The triple combination with finerenone addresses the residual inflammatory and fibrotic kidney pathways that neither class adequately covers alone. The principal limitation of this analysis is its review design — it integrates trial evidence but does not itself generate new outcome data. Real-world adoption of multi-drug staged regimens also faces adherence, cost, and access barriers not addressed in trial populations. Nonetheless, this represents one of the more rigorous attempts to operationalize emerging CKM biology into practical prescribing logic.